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relapse rates than those achieved with autologous transplants. 4 , 5 The concept of a graft-versus-lymphoma effect, however, remains unproven, because of the inclusion of Donor lymphocyte infusions, by virtue of a graft-versustumor effect, have been shown to induce remissions in heterogeneous patient populations in lymphoma studies and a high treatment-related mortality rate. leukemia that recurs after allogeneic bone marrow transplantation. Similar effects have been postulated to Discontinuation of immunosuppressive therapy or donor lymphocyte infusions have been successfully used to induce contribute to the decreased recurrence rate observed after allogeneic transplantation in non-Hodgkin's lymremissions in patients in whom disease has recurred after allogeneic transplantation for chronic or acute myelogenous phoma. This lower recurrence rate may be due to a variety of other mechanisms. We aimed to evaluate the role leukemia. 6 Similar observations have been reported for patients with multiple myeloma. 7 We have used immunoof graft-versus-lymphoma effects in patients in whom lymphomas recur after allogeneic transplantation. At logic manipulations in several patients with non-Hodgkin's lymphoma in whom disease recurred after allogeneic the time of recurrence, immunosuppressive therapy was withheld. Patients with non-responding disease received transplantation; complete or partial responses have been observed in four of nine patients. an infusion of donor lymphocytes. Patients were observed for response and graft-versus-host disease. Disease in four of nine patients responded to withdrawal Materials and methods of immunosuppressive therapy. A minor response was observed in one of three recipients of donor lymphocyte Patients infusions. Responses were observed among two patients with follicular lymphoma, one with large cell lymphoma Between April 1991 and July 1996, 77 patients with lymphoma underwent allogeneic bone marrow or stem cell and one with lymphoblastic lymphoma. A minor response was observed in a patient with prolymphocytic transplantation at the MD Anderson Cancer Center. Two had diffuse small non-cleaved cell lymphoma, 10 lymleukemia/lymphoma. We conclude that withdrawal of immunosuppressive therapy and donor lymphocyte phoblastic lymphoma, 26 low-grade lymphoma, 32 had de novo intermediate grade lymphoma and seven transformed infusion can induce durable remissions in patients with recurrent lymphoma after allogeneic transplantation.
lymphoma. Fifteen patients developed disease recurrence. One, with Burkitt's disease, died within a day of the diagKeywords: lymphoma; allogeneic transplantation; graftversus-lymphoma; recurrence nosis of disease recurrence. Two patients had graft failure prior to disease recurrence. They were treated with conventional chemotherapy and radiation. Three patients were cared for by their local physician at the time of recurrence. Bone marrow transplantation has been commonly used in Nine fully engrafted patients were cared for at the MD Andthe treatment of hematologic malignancies. Considerable erson Cancer Center at the time of disease recurrence. They data indicate that a graft-versus-leukemia effect occurs after form the subject of this report. allogeneic transplantation and that it contributes to the Details on conditioning, stem cell procurement and achievement of durable remissions in leukemia.
1,2 Synprophylaxis for graft-versus-host disease and infections geneic transplants and T cell-depleted allografts are assohave been previously reported. [8] [9] [10] [11] Two patients received ciated with an increased relapse rate, indicating that T cells conditioning consisting of cyclophosphamide, etoposide participate in the graft-versus-leukemia effect.
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(VP-16) and total body irradiation, 8 six patients received Allogeneic transplantation has also been used to treat high-dose thiotepa, busulfan and cyclophosphamide, 10 and non-Hodgkin's lymphoma, and several studies report lower one received BCNU, etoposide, cytarabine and melphalan. 12 Prophylaxis for graft-versus-host disease consisted of cyclosporine and short-course methotrexate (n = 
Immunologic manipulations at recurrence
stopped after which disease regression occurred in all sites of involvement ( Figure 1 ). The patient has developed Upon diagnosis of recurrence, several immunologic mani-GVHD of the gut and liver which is controlled with sterpulations were attempted. If the patient was receiving oids. His disease continues to be in remission 140 days cyclosporine or tacrolimus, it was discontinued. If the after withdrawal of tacrolimus. disease continued to progress after discontinuation of immunosuppression, and the patient remained in good condition, lymphocytes were collected from the allogeneic Patient 3 donor and infused into the patient without further prophy-A 35-year-old man with common variable immunodefilaxis for graft-versus-host disease. If a partial or complete ciency and autoimmune hemolytic anemia, was diagnosed response was obtained, this procedure could be repeated.
with stage IV follicular large cell lymphoma in October 1992. Only transient disease responses were obtained with the administration of several chemotherapeutic regimens.
Case reports
He underwent allogeneic BMT from his HLA-identical brother after conditioning with cyclophosphamide, etopoPatient characteristics and details on treatment and outcome side and total body irradiation. Prophylaxis for graft-versusare provided in Table 1 . Response to withdrawal of cyclohost disease consisted of cyclosporine and methotrexate. sporine or tacrolimus was observed in four patients: three The patient's disease entered complete remission. Seven patients who failed to respond to cyclosporine withdrawal, months after BMT, he presented with increasing liver functhen received an infusion of donor lymphocytes; a minor tion tests and paratracheal and retroperitoneal adenopathy; response was observed in one patient. The case histories of a liver biopsy showed B cell large-cell lymphoma. Cyclopatients with a response to immunologic manipulations are sporine was stopped. detailed below. Patient numbers in the case report refer to The patient's bilirubin level decreased from 4.3 to 1.1 numbers assigned in Table 1. mg/dl, but serum SGPT remained elevated. A repeat liver biopsy showed acute hepatitis with polyclonal lymphoid Patient 1 aggregates in the parenchyma. Oligonucleotide in situ hybridization did not reveal the presence of Epstein-Barr A 33-year-old man, presented in January 1991 with T cell virus RNA (EBER). An assay for hepatitis C RNA in the lymphoblastic lymphoma. After an initial response to comserum was positive, and interferon was started at 3 million bination chemotherapy, the patient developed leptomeninunits subcutaneously three times a week; all liver function geal disease. He received combined systemic and intratests normalized. Interferon was stopped after 6 months of thecal treatment and obtained a partial response.
therapy, but a relapse of hepatitis occurred that was docuHe underwent allogeneic BMT from his HLA-identical mented by a liver biopsy. There was no evidence of lymsister, after conditioning with thiotepa, busulfan, and cyclophoma. His liver function tests normalized after the reinstiphosphamide. Prophylaxis for graft-versus-host disease tution of interferon. consisted of cyclosporine and methylprednisolone. A comOne year after cyclosporine withdrawal, atypical lymplete response was achieved. Acute and chronic graftphocytes were detected in the bloodstream, and a bone marversus-host disease of the skin developed and required row biopsy revealed an interstitial lymphoid infiltrate that treatment with steroids and cyclosporine.
was suspicious for lymphoma. Flow cytometry was nonThirty-eight months after BMT, he presented with a diagnostic, but cytogenetic analysis of the marrow revealed biopsy-confirmed, isolated recurrence of lymphoblastic the following karyotype in 25% of the analyzed cells: lymphoma in the skin. Cyclosporine was stopped and ster-45,XY, del(2) (p21), −2, I(7)(q11.1), −7, −9, −11, oids were tapered. This resulted in a transient flare-up +del(14)(q21), +mar1. The remainder of the cells had a norof graft-versus-host disease of the skin and complete mal karyotype. Oligonucleotide in situ hybridization on resolution of the skin lesions. Twenty-four months after sections of the marrow did not show Epstein-Barr virus cessation of cyclosporine therapy, the patient's disease RNA, rendering the diagnosis of an EBV-related lymphopcontinues to be in remission.
roliferation unlikely. Twenty months after cyclosporine withdrawal, the patient remains asymptomatic and has not Patient 2 undergone further treatment.
A 41-year-old male was diagnosed with T cell-rich B cell large cell lymphoma in May 1995. He failed treatment with Patient 4 two consecutive chemotherapy regimens. He underwent allogeneic stem cell transplantation from his HLA-identical A 31-year-old woman was diagnosed with stage IV follicular small cleaved-cell lymphoma in May 1985. Only transibrother after conditioning with BCNU, etoposide, cytarabine and melphalan (BEAM). Prophylaxis for graft-versusent disease responses were obtained with the administration of several chemotherapeutic regimens. host disease consisted of tacrolimus and methotrexate. After a transient response, the patient's disease progressed She then underwent allogeneic BMT from her HLAidentical brother after conditioning with cyclophosphamide, in the liver, mediastinal and retroperitoneal lymph nodes on day 88 after transplant. Fine-needle aspiration demonetoposide, and total body irradiation. Prophylaxis for graftversus-host disease consisted of cyclosporine and methostrated the original disease histology. Tacrolimus was trexate. Acute grade 1 graft-versus-host disease of the skin graft-versus-host disease. Currently the patient is receiving monoclonal antibody treatment. developed and required treatment with steroids.
Three months after allogeneic BMT, her bone marrow showed persistent lymphoma, but subsequent biopsies Patient 5 revealed decreasing involvement. One year after BMT she presented with extensive chronic graft-versus-host disease A 53-year-old man was diagnosed in August 1994 with prolymphocytic leukemia. He presented with massive adenof the skin and esophagus, which was controlled with cyclosporine and methylprednisolone. Several attempts at opathy, blood and bone marrow involvement and failed treatment with two consecutive chemotherapy regimens. tapering the medications resulted in flare-ups of graftversus-host disease.
He underwent allogeneic peripheral blood stem cell transplant from his HLA-identical sister after conditioning Four years after BMT, a fine-needle aspiration of an enlarged lymph node in the left crus of the diaphragm with thiotepa, busulfan and cyclophosphamide. Prophylaxis for graft-versus-host disease consisted of cyclosporine and showed recurrent small cleaved-cell lymphoma. Cyclosporine was stopped, resulting in a decrease in the lymphadenomethylprednisolone. After initial tumor reduction, disease progression was documented in the bone marrow, lymph pathy without recurrence of graft-versus-host disease in the skin. Although a spontaneous remission of low-grade lymnodes and peripheral blood on day 75. Cyclosporine was stopped, resulting in a transient clearphoma could explain the decrease in adenopathy, 13 the temporal association with withdrawal of cyclosporine indicates ing of circulating lymphoma cells. No effect on the bone marrow or lymph nodes was observed. On days +99 and a graft-versus-lymphoma effect. Nine months later, progression of adenopathy was documented. The patient did +100 after allogeneic BMT, he received a donor lymphocyte infusion, after which clearance of lymphoma cells not respond to treatment with interferon. Donor lymphocyte infusion was not considered for fear of provoking recurrent from the blood was documented. Graft-versus-host disease of the skin and profound pancytopenia developed. The mia patients, the response to donor lymphocyte infusion depends on disease histology. 6 Based on the low recurrence patient received a boost of G-CSF-mobilized donor stem cells on day +139. Despite the response in the peripheral rates after allogeneic BMT for low-grade lymphoma, similar differences in sensitivity to GVL effects may be true blood, no response was documented in the bone marrow or other disease sites, and the patient died at day +156 after among lymphoma subtypes. 9 Our observations on the effect of cyclosporine withdrawal however are currently too allogeneic BMT as a result of disease progression and Candida krusei sepsis.
limited to allow such conclusions.
In conclusion, immune modulations may induce graftversus-lymphoma effects that result in tumor regression in different histologic subtypes of lymphoma. Therapeutic Discussion strategies aimed at exploiting such effects should be further evaluated in a systematic fashion. The high incidence of aggressive lymphoid malignancy in AIDS patients 14 and among organ transplantation recipients 15 indicates that immune deficiency plays a pivotal role in the pathogenesis of these malignancies. The susceptiReferences bility of lymphoma to host defense mechanisms is further illustrated by the observation of spontaneous remissions ous BMT. 5, 22 There have also been reports of successful
